Annual EBIT
-$229.31 M
+$66.49 M+22.48%
December 31, 2023
Summary
- As of February 8, 2025, ARQT annual earnings before interest & taxes is -$229.31 million, with the most recent change of +$66.49 million (+22.48%) on December 31, 2023.
- During the last 3 years, ARQT annual EBIT has fallen by -$93.64 million (-69.01%).
- ARQT annual EBIT is now -5484.88% below its all-time high of -$4.11 million, reached on December 31, 2017.
Performance
ARQT EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$34.88 M
+$9.96 M+22.22%
September 30, 2024
Summary
- As of February 8, 2025, ARQT quarterly earnings before interest & taxes is -$34.88 million, with the most recent change of +$9.96 million (+22.22%) on September 30, 2024.
- Over the past year, ARQT quarterly EBIT has dropped by -$701.00 thousand (-2.05%).
- ARQT quarterly EBIT is now -485.99% below its all-time high of -$5.95 million, reached on December 31, 2018.
Performance
ARQT Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$165.81 M
-$701.00 K-0.42%
September 30, 2024
Summary
- As of February 8, 2025, ARQT TTM earnings before interest & taxes is -$165.81 million, with the most recent change of -$701.00 thousand (-0.42%) on September 30, 2024.
- Over the past year, ARQT TTM EBIT has increased by +$70.18 million (+29.74%).
- ARQT TTM EBIT is now -2685.27% below its all-time high of -$5.95 million, reached on December 31, 2018.
Performance
ARQT TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
ARQT EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.5% | -2.0% | +29.7% |
| 3 y3 years | -69.0% | -2.0% | +29.7% |
| 5 y5 years | -1062.0% | -2.0% | +29.7% |
ARQT EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -11.1% | +22.5% | -26.5% | +66.1% | -0.4% | +45.9% |
| 5 y | 5-year | -431.7% | +22.5% | -168.5% | +66.1% | -284.4% | +45.9% |
| alltime | all time | -5484.9% | +22.5% | -486.0% | +66.1% | -2685.3% | +45.9% |
Arcutis Biotherapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$34.88 M(-22.2%) | -$165.81 M(+0.4%) |
| Jun 2024 | - | -$44.85 M(+62.6%) | -$165.11 M(-10.2%) |
| Mar 2024 | - | -$27.58 M(-52.9%) | -$183.90 M(-19.8%) |
| Dec 2023 | -$229.31 M(-22.5%) | -$58.50 M(+71.1%) | -$229.38 M(-2.8%) |
| Sep 2023 | - | -$34.18 M(-46.3%) | -$235.99 M(-22.5%) |
| Jun 2023 | - | -$63.64 M(-12.9%) | -$304.61 M(-0.6%) |
| Mar 2023 | - | -$73.06 M(+12.2%) | -$306.38 M(+3.6%) |
| Dec 2022 | -$295.81 M(+43.3%) | -$65.10 M(-36.7%) | -$295.81 M(-2.1%) |
| Sep 2022 | - | -$102.81 M(+57.2%) | -$302.03 M(+17.9%) |
| Jun 2022 | - | -$65.41 M(+4.7%) | -$256.20 M(+10.1%) |
| Mar 2022 | - | -$62.49 M(-12.4%) | -$232.80 M(+12.8%) |
| Dec 2021 | -$206.36 M | -$71.33 M(+25.2%) | -$206.36 M(+22.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$56.98 M(+35.6%) | -$168.13 M(+12.5%) |
| Jun 2021 | - | -$42.01 M(+16.6%) | -$149.45 M(+4.5%) |
| Mar 2021 | - | -$36.04 M(+8.9%) | -$143.07 M(+5.4%) |
| Dec 2020 | -$135.68 M(+214.6%) | -$33.10 M(-13.6%) | -$135.68 M(+17.4%) |
| Sep 2020 | - | -$38.30 M(+7.5%) | -$115.58 M(+25.7%) |
| Jun 2020 | - | -$35.63 M(+24.3%) | -$91.92 M(+41.8%) |
| Mar 2020 | - | -$28.65 M(+120.5%) | -$64.83 M(+50.3%) |
| Dec 2019 | -$43.13 M(+118.6%) | -$12.99 M(-11.3%) | -$43.13 M(+19.5%) |
| Sep 2019 | - | -$14.65 M(+71.6%) | -$36.09 M(+68.3%) |
| Jun 2019 | - | -$8.54 M(+22.8%) | -$21.44 M(+66.2%) |
| Mar 2019 | - | -$6.95 M(+16.8%) | -$12.90 M(+116.8%) |
| Dec 2018 | -$19.73 M(+380.6%) | -$5.95 M | -$5.95 M |
| Dec 2017 | -$4.11 M | - | - |
FAQ
- What is Arcutis Biotherapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Arcutis Biotherapeutics?
- What is Arcutis Biotherapeutics annual EBIT year-on-year change?
- What is Arcutis Biotherapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Arcutis Biotherapeutics?
- What is Arcutis Biotherapeutics quarterly EBIT year-on-year change?
- What is Arcutis Biotherapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Arcutis Biotherapeutics?
- What is Arcutis Biotherapeutics TTM EBIT year-on-year change?
What is Arcutis Biotherapeutics annual earnings before interest & taxes?
The current annual EBIT of ARQT is -$229.31 M
What is the all time high annual EBIT for Arcutis Biotherapeutics?
Arcutis Biotherapeutics all-time high annual earnings before interest & taxes is -$4.11 M
What is Arcutis Biotherapeutics annual EBIT year-on-year change?
Over the past year, ARQT annual earnings before interest & taxes has changed by +$66.49 M (+22.48%)
What is Arcutis Biotherapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of ARQT is -$34.88 M
What is the all time high quarterly EBIT for Arcutis Biotherapeutics?
Arcutis Biotherapeutics all-time high quarterly earnings before interest & taxes is -$5.95 M
What is Arcutis Biotherapeutics quarterly EBIT year-on-year change?
Over the past year, ARQT quarterly earnings before interest & taxes has changed by -$701.00 K (-2.05%)
What is Arcutis Biotherapeutics TTM earnings before interest & taxes?
The current TTM EBIT of ARQT is -$165.81 M
What is the all time high TTM EBIT for Arcutis Biotherapeutics?
Arcutis Biotherapeutics all-time high TTM earnings before interest & taxes is -$5.95 M
What is Arcutis Biotherapeutics TTM EBIT year-on-year change?
Over the past year, ARQT TTM earnings before interest & taxes has changed by +$70.18 M (+29.74%)